Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2021 Jul;144(1):58-66.
doi: 10.1111/ane.13422. Epub 2021 Mar 31.

Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis

Lanlan Zhang  1 , Juan Wang  1 , Chengzhong Wang  1
Affiliations
Meta-Analysis

Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta-analysis

Lanlan Zhang et al. Acta Neurol Scand. 2021 Jul.

Abstract

Objective: To investigate the efficacy and safety of adjunctive cenobamate for treatment of uncontrolled focal seizures.

Methods: We performed a systematic search of Web of Science, MEDLINE (Ovid and PubMed), Cochrane Library, EMBASE and Google Scholar to identify eligible studies. We included randomized placebo-controlled trials (RCTs) for uncontrolled focal seizures. We calculated the risk ratio (RR) of ≥50%, ≥75% and 100% reduction in seizure frequency from baseline, as well as dropout and serious adverse events related to treatment. Quality of included trials was assessed using the Cochrane Collaboration's tool.

Results: Two RCTs with a total of 658 patients were included. A significantly larger proportion of patients allocated to cenobamate achieved 50% seizure reduction (RR 2.06, 95% CI 1.70-2.51, p < 0.001) as compared to placebo, subgroup analysis demonstrated that the most effective dose was at 400 mg (RR 2.28, 95% CI 1.57-3.32, p < 0.001). Patients achieving seizure-freedom during the treatment period were 14.9% with cenobamate and 4.5% with placebo (RR 5.32, 95% CI 2.94-9.62, p < 0.001). Dropouts (RR 1.40, 95% CI 1.01-1.94, p = 0.05) and incidence of serious adverse events (RR 1.48, 95% CI 0.93-2.33, p = 0.1) were not significantly higher in patients receiving cenobamate. However, subgroup analyses based on doses suggested that patients exposed to 400 mg cenobamate were more likely to dropout than placebo (RR 2.09, 95% CI 1.17- 3.71, p = 0.012).

Conclusion: Cenobamate demonstrated favourable efficacy for treatment of uncontrolled focal seizures and showed a dose-related fashion. Cenobamate could be well tolerated, the most common adverse events associated with cenobamate were dizziness, somnolence, fatigue, headache and nausea. Nevertheless, majority of them were mild to moderate in severity.

Keywords: adverse event; cenobamate; meta-analysis; randomized controlled trial; uncontrolled focal seizures.

PubMed Disclaimer

References

REFERENCES

    1. Patel AD, Baca C, Franklin G, et al. Quality improvement in neurology: epilepsy quality measurement set 2017 update. Neurology. 2018;91:829-836.
    1. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-year longitudinal cohort study. JAMA Neurol. 2018;75:279-286.
    1. Tian N, Boring M, Kobau R, Zack MM, Croft JB. Active epilepsy and seizure control in adults - United States, 2013 and 2015. MMWR Morb Mortal Wkly Rep. 2018;67:437-442.
    1. Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012;78:1548-1554.
    1. Hauser WA. Questioning the effectiveness of newer antiseizure medications. JAMA Neurol. 2018;75:273-274.

MeSH terms

LinkOut - more resources